Innoviva Inventory 2010-2024 | INVA

Innoviva inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
Innoviva Annual Inventory
(Millions of US $)
2023 $41
2022 $56
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $10
2012 $8
2011 $
2010 $
2009 $
Innoviva Quarterly Inventory
(Millions of US $)
2024-09-30 $34
2024-06-30 $37
2024-03-31 $37
2023-12-31 $41
2023-09-30 $41
2023-06-30 $47
2023-03-31 $50
2022-12-31 $56
2022-09-30 $71
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31 $11
2013-12-31 $10
2013-09-30 $9
2013-06-30 $8
2013-03-31 $8
2012-12-31 $8
2012-09-30 $5
2012-06-30 $4
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.195B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03